Literature DB >> 19847433

Coexistent pyoderma gangrenosum and tibialis anterior myositis as presenting manifestations of Crohn's disease: case report and review of the literature.

Oran Goldshmid1, Zamir Dovorish, Tania Zehavi, Alon Eisen, Yaron Bar-Dayan, Howard Amital.   

Abstract

Crohn's disease (CD) is a well defined inflammatory bowel disease. Patients primarily present with abdominal pain and diarrhea, however, extra-intestinal manifestations due to musculoskeletal and cutaneous involvement are seen in a varying range of patients. In this communication we describe a young woman who presented with a severe inflammatory illness that consequently developed into pyoderma gangrenosum, anterior tibialis myositis and arthritis that were all antecedent to the intestinal involvement. The patient favorably responded to infliximab with concomitant azathioprine therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19847433     DOI: 10.1007/s00296-009-1168-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  9 in total

Review 1.  Localised gastrocnemius myositis in Crohn's disease.

Authors:  C Christopoulos; S Savva; S Pylarinou; A Diakakis; E Papavassiliou; P Economopoulos
Journal:  Clin Rheumatol       Date:  2003-05       Impact factor: 2.980

Review 2.  Skeletal muscle disorders associated with inflammatory bowel diseases: occurrence of myositis in a patient with ulcerative colitis and Hashimoto's thyroiditis--case report and review of the literature.

Authors:  Omero Alessandro Paoluzi; Pietro Crispino; Margherita Rivera; Federico Iacopini; Dino Palladini; Adriana Consolazio; Paolo Paoluzi
Journal:  Int J Colorectal Dis       Date:  2005-10-05       Impact factor: 2.571

Review 3.  Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis.

Authors:  K M Das
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

Review 4.  Extraintestinal manifestations and complications in inflammatory bowel diseases.

Authors:  Katja S Rothfuss; Eduard F Stange; Klaus R Herrlinger
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

5.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.

Authors:  T N Brooklyn; M G S Dunnill; A Shetty; J J Bowden; J D L Williams; C E M Griffiths; A Forbes; R Greenwood; C S Probert
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

Review 6.  Inflammatory bowel disease and myositis.

Authors:  Y Braun-Moscovici; D Schapira; A Balbir-Gurman; A M Nahir
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

Review 7.  Extraintestinal manifestations of inflammatory bowel disease.

Authors:  C N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  2001-12

8.  Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease.

Authors:  Folashade Adebisi Jose; Elizabeth A Garnett; Eric Vittinghoff; George D Ferry; Harland S Winter; Robert N Baldassano; Barbara S Kirschner; Stanley A Cohen; Benjamin D Gold; Oren Abramson; Melvin B Heyman
Journal:  Inflamm Bowel Dis       Date:  2009-01       Impact factor: 5.325

9.  Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease.

Authors:  Yoram Menachem; Israel Gotsman
Journal:  Isr Med Assoc J       Date:  2004-02       Impact factor: 0.892

  9 in total
  3 in total

1.  [Differential diagnosis of a vasculitic syndrome of the lower limb].

Authors:  Nikolas Ruffer; Martin Krusche; Marie-Therese Holzer; Christian Hagel; Ina Kötter
Journal:  Z Rheumatol       Date:  2021-07-09       Impact factor: 1.372

2.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

3.  Crohn's disease-related 'gastrocnemius myalgia syndrome' successfully treated with infliximab: A case report.

Authors:  Julien Catherine; Hazim Kadhim; Frédéric Lambot; Claire Liefferinckx; Virginie Meurant; Lukas Otero Sanchez
Journal:  World J Gastroenterol       Date:  2022-02-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.